Interleukin-6 May Boost Prediction of Obesity-Related Cancers
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 3, 2024 -- In patients with newly diagnosed type 2 diabetes, baseline interleukin-6 (IL-6) levels may enhance prediction of new-onset obesity-related cancers, according to a study scheduled to be presented at the annual meeting of the European Association for the Study of Diabetes, being held from Sept. 9 to 13 in Madrid.
Mathilde Dahlin Bennetsen, from the Steno Diabetes Center Odense at Odense University Hospital in Denmark, and colleagues explored whether IL-6, tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hsCRP) can serve as predictive biomarkers for obesity-related cancers in patients recently diagnosed with type 2 diabetes. The analysis included 6,466 individuals followed for a median 8.8 years.
The researchers found that baseline IL-6 levels were associated with a higher subsequent obesity-related cancer risk. A one standard deviation increase in log-transformed IL-6 was tied to a 19 percent increased risk for obesity-related cancers in an adjusted analysis (hazard ratio, 1.19; 95 percent confidence interval, 1.07 to 1.31). There was no strong association seen between TNF-α (hazard ratio, 1.08; 95 percent confidence interval, 0.98 to 1.19) or hsCRP (hazard ratio, 1.08; 95 percent confidence interval, 0.97 to 1.21) and obesity-related cancers. In 4,335 participants with available smoking habit information, similar associations were seen. The addition of IL-6 to a cancer prediction model conferred a small but statistically significant increase in the C-index, from 0.685 to 0.693, whereas the addition of hsCRP or TNF-α did not result in improvements in model performance.
"Understanding which individuals are at higher risk for these cancers would allow for more targeted and effective monitoring and early detection, potentially improving outcomes through earlier intervention and personalized treatment," Bennetsen said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
TUESDAY, April 29, 2025 -- Patients with cancer aged 65 years and older receiving immune checkpoint inhibitors (ICIs) derive similar clinical outcomes as younger patients...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.